 | |
 | |
| Clinical data | |
|---|---|
| Trade names | Brovana |
| Other names | Arformoterol tartrate (USANUS) |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a602023 |
| License data | |
| Routes of administration | Inhalation |
| ATC code |
|
| Legal status | |
| Legal status | |
| Pharmacokinetic data | |
| Protein binding | 52–65% |
| Eliminationhalf-life | 26 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| DrugBank |
|
| ChemSpider |
|
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C19H24N2O4 |
| Molar mass | 344.411 g·mol−1 |
| |
 N Y (what is this?) (verify) | |
Arformoterol, sold under the brand nameBrovana among others, is amedication used for the treatment ofchronic obstructive pulmonary disease (COPD).[1][2]
It is along-acting β2 adrenoreceptor agonist (LABA) and it is the active (R,R)-(−)-enantiomer offormoterol.[1] It was approved for medical use in the United States in October 2006.[1] It is available as ageneric medication.[3]
Arformoterol isindicated for the maintenance treatment of bronchoconstriction in people with chronic obstructive pulmonary disease (COPD).[1]
 | Thisdrug article relating to therespiratory system is astub. You can help Wikipedia byexpanding it. |
